Quantcast
Last updated on April 24, 2014 at 16:36 EDT

Latest Perrigo Company Stories

2012-01-12 07:51:00

ALLEGAN, Mich., Jan. 12, 2011 /PRNewswire/ -- Perrigo Company (NASDAQ: PRGO; TASE) announced today that the United States District Court for the Western District of Michigan has granted summary judgment in its favor in patent litigation involving Guaifenesin Extended-Release Tablets, 600 mg, a generic version of Mucinex® tablets. Perrigo had been sued by Adams Respiratory Therapeutics, Inc., (a subsidiary of Reckitt Benckiser Group plc.) the New Drug Application holder...

2012-01-09 07:30:00

ALLEGAN, Mich., Jan. 9, 2012 /PRNewswire/ -- Perrigo Company (Nasdaq: PRGO; TASE) today announced that it has signed a definitive agreement to acquire substantially all of the assets of CanAm Care, a privately-held, Alpharetta, Georgia-based distributor of diabetes care products for approximately $36 million in cash. The acquisition is expected to be immediately accretive to adjusted earnings per share. The assets acquired from CanAm Care include: Dex4® hypoglycemia products (tabs,...

2012-01-06 07:54:00

ALLEGAN, Mich., Jan. 6, 2012 /PRNewswire/ -- Perrigo Company (Nasdaq: PRGO;TASE) today announced that Perrigo Chairman and CEO Joseph C. Papa will present at the 30th Annual J.P. Morgan Healthcare Conference on Monday, January 9, at 10:30 AM (PST) at the Westin St. Francis Hotel in San Francisco, CA. The presentation will be webcast at the following link: http://jpmorgan.metameetings.com/webcasts/healthcare12/?sessionId=9bb4fd7d0105162325790. Perrigo Company is a leading global healthcare...

2011-12-29 08:30:00

CHICAGO, Dec. 29, 2011 /PRNewswire/ -- Today, Zacks Equity Research discusses the Pharma & Biotech, including Vertex Pharma (Nasdaq: VRTX), Human Genome Sciences Inc. (Nasdaq: HGSI), Biogen Idec (Nasdaq: BIIB) and Perrigo Company (Nasdaq: PRGO). (Logo: http://photos.prnewswire.com/prnh/20101027/ZIRLOGO) A synopsis of today's Industry Outlook is presented below. The full article can be read at...

2011-12-27 08:29:00

ALLEGAN, Mich., Dec. 27, 2011 /PRNewswire/ -- Perrigo Company (Nasdaq: PRGO;TASE) today announced that it has received final approval from the U.S. Food and Drug Administration for its abbreviated new drug application (ANDA) for Desloratadine tablets (5 mg). Perrigo had been sued for patent infringement based upon its filing of an ANDA containing a Paragraph IV certification and settled the case in 2008. Under the terms of the settlement, Perrigo can commercially launch its...

2011-11-28 07:04:00

ALLEGAN, Mich., Nov. 28, 2011 /PRNewswire/ -- Perrigo Company (Nasdaq: PRGO; TASE) today announced that it received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Guaifenesin Extended-Release Tablets, 600 mg. The new product will be packaged under store and proprietary brands that will compare to Mucinex® tablets. Perrigo is still in litigation with Reckitt Benckiser Group, PLC, the New Drug...

2011-11-15 07:32:00

ALLEGAN, Mich., Nov. 15, 2011 /PRNewswire/ -- Perrigo Company (NASDAQ: PRGO; TASE) today announced it received Food and Drug Administration (FDA) clearance to market and distribute infant formula that contains 100 percent partially hydrolyzed whey protein. The store brand Comfort Care(TM) Infant Formula is designed for babies with fussiness or gas and will be sold as a nutritionally comparable version of Gerber® GOOD START® Gentle Infant Formula at...

2011-11-10 14:40:00

BOTHELL, Wash., Nov. 10, 2011 /PRNewswire/ -- SCOLR Pharma, Inc. (OTC: SCLR) today reported financial results for the three months and nine months ended September 30, 2011. Stephen Turner, President and CEO, said: "We continue to move forward with our nutritional business and are receiving positive response from the retailers. We are optimistic that our extended-release nutritional products, which we are aggressively marketing, will be successful as they enter retail channels." Third...

2011-11-08 10:35:00

ALLEGAN, Mich., Nov. 8, 2011 /PRNewswire/ -- Perrigo Company (Nasdaq: PRGO; TASE) today announced that it has entered into Cooperation and License agreements with Brilite Nutritionals (Shanghai) Co., Ltd. ("Brilite"), a Shanghai based infant nutrition company. Under these agreements, Perrigo will supply its Bright Beginnings(TM) infant formula brand to Brilite, which will exclusively source all its infant formula requirements from Perrigo's U.S. manufacturing facilities, for sale and...

2011-11-07 09:24:00

ALLEGAN, Mich., Nov. 7, 2011 /PRNewswire/ -- Perrigo Company (Nasdaq: PRGO; TASE) and its partner Synthon Pharmaceuticals, Inc. today announced that Perrigo has begun shipping Levocetirizine Solution, 2.5 mg/5ml, a generic version of UCB's Xyzal® Oral Solution. Synthon has the first to file ANDA application for the generic that entitle it to 180 days of generic exclusivity. Hatch Waxman litigation in this product was settled earlier this year. Perrigo is the manufacturer...